BofA analyst Tim Anderson lowered the firm’s price target on AbbVie (ABBV) to $248 from $251 and keeps a Neutral rating on the shares. While stating that AbbVie reported a “good quarter overall,” the firm thinks the beat-and-raise was “perhaps not by enough,” which it says partly reflects a stock that is “priced for perfection.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: